vicasinabin (RG7774)
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
January 13, 2025
CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy.
(PubMed, Ophthalmol Sci)
- P2 | "The objective of CANBERRA was to assess the safety, tolerability, and efficacy of oral administration of vicasinabin (RG7774) on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe NPDR and good vision...EUDRACT number: 2019-002067-10. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."
Clinical • Journal • P2 data • Cardiovascular • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus
September 25, 2024
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=139 | Completed | Sponsor: Hoffmann-La Roche | N=104 ➔ 139
Enrollment change • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
July 29, 2024
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
(PubMed, Front Pharmacol)
- "RG7774 is a novel, highly selective, and orally bioavailable CB2R agonist, with an acceptable systemic and ocular PK profile, and beneficial effects on retinal vascular permeability, leukocyte adhesion, and ocular inflammation in rodent animal models. Results support the development of RG7774 as a potential treatment for retinal diseases with similar pathophysiologies as addressed by the animal models."
Journal • Preclinical • Diabetic Retinopathy • Inflammation • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis
July 27, 2023
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=104 | Completed | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
December 09, 2022
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=104 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
September 19, 2022
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=135 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting
Enrollment open • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
August 22, 2022
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=135 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
February 10, 2022
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2 | N=135 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2022 ➔ Jun 2023 | Trial primary completion date: Feb 2022 ➔ Jun 2023
Trial completion date • Trial primary completion date • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 1 Diabetes Mellitus
April 27, 2020
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2; N=135; Not yet recruiting; Sponsor: Hoffmann-La Roche; Initiation date: Mar 2020 ➔ Sep 2020
Clinical • Trial initiation date • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 1 Diabetes Mellitus
March 05, 2020
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2; N=135; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
February 11, 2020
CANBERRA: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
(clinicaltrials.gov)
- P2; N=135; Not yet recruiting; Sponsor: Hoffmann-La Roche
Clinical • New P2 trial
1 to 11
Of
11
Go to page
1